December 3, 2014: Plasma Gelsolin Patent for Therapeutic Use in Renal Failure Granted in Europe

December 3, 2014

Patent Covers Therapeutic Uses of Plasma Gelsolin in Renal Failure

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – December 3, 2014) BioAegis Therapeutics announces that its portfolio of patents has been expanded with the granting of a second European Patent for plasma gelsolin. Claims in this patent are directed to the treatment of renal failure.

December 3, 2014: Plasma Gelsolin Patent for Therapeutic Use in Renal Failure Granted in Europe

Stay informed of our latest discoveries and news.

GENERAL NEWS/MEDIA

February 27, 2024: BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)

October 16, 2023: BioAegis Therapeutics Awarded $20 Million BARDA DRIVe Contract to Advance Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)

May 2023: BioAegis Therapeutics to Sponsor a Webinar, Below the Eyes of the Hippopotamus: The Expanding Spectrum of Auto- and Hyper- Inflammatory Diseases

EVENTS

May 23, 2023: Below the Eyes of the Hippopotamus: The Expanding Spectrum of Auto- and Hyper- Inflammatory Diseases

COMPANY DETAILS

JOIN OUR TEAM

PRODUCT FAQS

FOLLOW US